Structures by: Wang H. B.
Total: 166
C21H21NO6
C21H21NO6
Journal of natural products (2019) 82, 10 2713-2720
a=19.2610(9)Å b=6.1061(3)Å c=16.8271(10)Å
α=90° β=114.670(6)° γ=90°
C21H21NO6
C21H21NO6
Journal of natural products (2019) 82, 10 2713-2720
a=7.21184(12)Å b=8.25750(15)Å c=29.7262(5)Å
α=90° β=90° γ=90°
C23H27NO6,6(O)
C23H27NO6,6(O)
Journal of natural products (2019) 82, 10 2713-2720
a=16.2110(2)Å b=8.33626(11)Å c=19.9088(3)Å
α=90° β=101.1180(13)° γ=90°
C20H16O5
C20H16O5
Organic Chemistry Frontiers (2016) 3, 2 217
a=7.1154(3)Å b=11.1585(5)Å c=11.1645(5)Å
α=107.811(3)° β=95.510(3)° γ=91.238(3)°
C14H14N4O
C14H14N4O
Organic & biomolecular chemistry (2018) 16, 16 2947-2954
a=7.753(2)Å b=14.532(4)Å c=11.144(3)Å
α=90° β=98.574(6)° γ=90°
C14H14N4O
C14H14N4O
Chemical communications (Cambridge, England) (2018) 54, 71 9897-9900
a=7.753(2)Å b=14.532(4)Å c=11.144(3)Å
α=90° β=98.574(6)° γ=90°
C27H34BBr3F4N9Ni2O3
C27H34BBr3F4N9Ni2O3
New J. Chem. (2014) 38, 10 5037
a=12.5179(4)Å b=12.1239(4)Å c=22.7490(7)Å
α=90.00° β=93.3390(10)° γ=90.00°
C54H71BN12Ni2O6
C54H71BN12Ni2O6
New J. Chem. (2014) 38, 10 5037
a=9.1157(18)Å b=30.055(6)Å c=21.282(4)Å
α=90.00° β=93.25(3)° γ=90.00°
C27H33BBr3F4N9Ni2O3
C27H33BBr3F4N9Ni2O3
New J. Chem. (2014) 38, 10 5037
a=12.518(3)Å b=12.124(2)Å c=22.749(5)Å
α=90.00° β=93.34(3)° γ=90.00°
C27H33Br3ClN9Ni2O7
C27H33Br3ClN9Ni2O7
New J. Chem. (2014) 38, 10 5037
a=11.763(2)Å b=12.496(3)Å c=23.866(5)Å
α=90.00° β=90.00° γ=90.00°
C52H76Cl2N26Ni5O19
C52H76Cl2N26Ni5O19
New J. Chem. (2014) 38, 10 5037
a=18.717(6)Å b=25.333(8)Å c=17.423(5)Å
α=90° β=99.435(6)° γ=90°
C23H28CdN2O9
C23H28CdN2O9
CrystEngComm (2015) 17, 47 9055
a=21.234(9)Å b=15.744(6)Å c=16.213(7)Å
α=90° β=113.443(4)° γ=90°
C50H45Cd2N9O13
C50H45Cd2N9O13
CrystEngComm (2015) 17, 47 9055
a=17.6240(11)Å b=11.8156(7)Å c=26.1460(13)Å
α=90° β=116.317(3)° γ=90°
C44H39Cl3N6O6S3
C44H39Cl3N6O6S3
Chemical communications (Cambridge, England) (2010) 46, 39 7343-7345
a=12.1851(4)Å b=12.7756(4)Å c=15.7666(5)Å
α=82.4650(10)° β=77.9780(10)° γ=70.3200(10)°
C22H19N3O2S
C22H19N3O2S
Chemical communications (Cambridge, England) (2010) 46, 39 7343-7345
a=27.937(6)Å b=6.7394(13)Å c=9.871(2)Å
α=90.00° β=92.11(3)° γ=90.00°
[C3-APy][Ni(dmit2)]3
C26H13N2Ni3S30
RSC Adv. (2015)
a=11.5235(13)Å b=12.6902(13)Å c=19.485(2)Å
α=74.904(3)° β=75.852(4)° γ=63.906(3)°
C48H48Co2N8O10
C48H48Co2N8O10
Dalton transactions (Cambridge, England : 2003) (2014) 43, 41 15450-15456
a=11.020(2)Å b=9.7200(19)Å c=21.600(4)Å
α=90.00° β=96.00(3)° γ=90.00°
C86H82Cl2Co5N16O22
C86H82Cl2Co5N16O22
Dalton transactions (Cambridge, England : 2003) (2014) 43, 41 15450-15456
a=11.949(6)Å b=12.429(5)Å c=16.064(7)Å
α=93.020(8)° β=94.659(5)° γ=101.286(6)°
<i>catena</i>-Poly[[diaquacobalt(II)]-bis[μ-5-(4-carboxylatophenyl)picolinato]-κ^3^<i>N</i>,<i>O</i>^2^:<i>O</i>^5^;κ^3^<i>O</i>^5^:<i>N</i>,<i>O</i>^2^-[diaquacobalt(II)]-μ-1-[4-(1<i>H</i>-imidazol-1-yl)phenyl]-1<i>H</i>-imidazole-κ^2^<i>N</i>^3^:<i>N</i>^3^]
C19H16CoN3O6
Acta Crystallographica Section E (2015) 71, 7 m145-m146
a=7.055(3)Å b=7.190(3)Å c=20.038(10)Å
α=80.25(2)° β=79.90(2)° γ=64.080(15)°
Methyl 3-dimethylamino-2-{2-[2-(dimethylamino)-1-(3-phenyl-1,2,4-oxadiazol-5- yl)vinyloxy]phenyl}acrylate
C24H26N4O4
Acta Crystallographica Section E (2004) 60, 10 o1709-o1711
a=11.220(2)Å b=12.260(3)Å c=17.762(4)Å
α=71.06(3)° β=86.35(3)° γ=85.19(3)°
Methyl 3-(dimethylamino)-2-(2-{1-[3-(2-methylphenyl)-1,2,4-oxadiazol -5-yl]-2-(dimethylamino)vinyloxyl}phenyl)acrylate
C25H28N4O4
Acta Crystallographica Section E (2005) 61, 5 o1426-o1428
a=10.250(2)Å b=10.691(2)Å c=12.263(3)Å
α=105.46(3)° β=110.74(3)° γ=92.30(3)°
Methyl 2-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenylacetate
C18H15FN2O4
Acta Crystallographica Section E (2006) 62, 7 o2689-o2690
a=11.603(2)Å b=9.0170(18)Å c=15.692(3)Å
α=90.00° β=96.90(3)° γ=90.00°
[3-(2-Chlorophenyl)-1,2,4-oxadiazol-5-yl]methanol
C9H7ClN2O2
Acta Crystallographica Section E (2006) 62, 7 o3007-o3008
a=7.4280(15)Å b=14.202(3)Å c=8.8050(18)Å
α=90.00° β=106.76(3)° γ=90.00°
4-Methylbenzamidoxime
C8H10N2O
Acta Crystallographica Section E (2006) 62, 7 o3105-o3106
a=6.4220(13)Å b=7.4720(15)Å c=17.181(3)Å
α=79.48(3)° β=82.16(3)° γ=85.45(3)°
4-{[3-(2-Chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl}-1-[(2,6- dimethylphenyl)aminocarbonylmethyl]piperazine
C23H26ClN5O2
Acta Crystallographica Section E (2005) 61, 7 o1994-o1996
a=12.2960(10)Å b=10.587(2)Å c=17.164(2)Å
α=90.00° β=99.77(3)° γ=90.00°
Methyl 2-{[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl]methoxy}phenylacetate
C19H18N2O5
Acta Crystallographica Section E (2006) 62, 5 o1839-o1840
a=8.9620(18)Å b=7.9500(16)Å c=25.021(5)Å
α=90.00° β=96.51(3)° γ=90.00°
1-Acetyl-3,3-bis[3-(4-methylphenyl)-1,2,4-oxadiazol-5-ylmethyl]-1H- indol-2(3H)-one
C30H25N5O4
Acta Crystallographica Section E (2006) 62, 6 o2462-o2463
a=15.5510(16)Å b=6.9695(14)Å c=25.220(2)Å
α=90.00° β=103.46(3)° γ=90.00°
4'-Bromomethyl-2-cyanobiphenyl
C14H10BrN
Acta Crystallographica Section E (2003) 59, 12 o1944-o1945
a=47.219(12)Å b=24.229(6)Å c=4.1085(10)Å
α=90.00° β=90.00° γ=90.00°
1-[(2,6-Dimethylphenyl)aminocarbonylmethyl]- 4-{[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]methyl}piperazine
C23H26N6O4
Acta Crystallographica Section E (2004) 60, 11 o2041-o2042
a=7.2240(14)Å b=9.5650(19)Å c=33.245(7)Å
α=90.00° β=95.22(3)° γ=90.00°
3,3-Dibenzylbenzo[b]furan-2(3H)-one
C22H18O2
Acta Crystallographica Section E (2004) 60, 10 o1842-o1843
a=12.650(3)Å b=15.488(3)Å c=8.772(2)Å
α=90.00° β=90.00° γ=90.00°
Methyl {2-[(3-phenyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl}acetate
C18H16N2O4
Acta Crystallographica Section E (2004) 60, 9 o1478-o1480
a=8.7850(18)Å b=9.848(2)Å c=10.345(2)Å
α=77.90(3)° β=79.12(3)° γ=67.39(3)°
Methyl 2-{[3-(2-methyl)phenyl-1,2,4-oxadiazol-5-yl]methoxy}phenylacetate
C19H18N2O4
Acta Crystallographica Section E (2005) 61, 5 o1390-o1392
a=11.444(2)Å b=7.9540(16)Å c=19.356(4)Å
α=90.00° β=102.83(3)° γ=90.00°
3-[3-(Methoxyl)phenyl]-5-chloromethyl-1,2,4-oxadiazole
C10H9ClN2O2
Acta Crystallographica Section E (2005) 61, 5 o1446-o1447
a=7.2350(14)Å b=9.5600(19)Å c=15.454(3)Å
α=90.00° β=97.03(3)° γ=90.00°
Methyl 2-[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenylacetate
C18H15ClN2O4
Acta Crystallographica Section E (2005) 61, 6 o1858-o1860
a=11.314(2)Å b=7.9510(16)Å c=19.598(4)Å
α=90.00° β=103.08(3)° γ=90.00°
Methyl 2-(2-{1-[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]-2- (dimethylamino)vinyloxy}phenyl)-3-(dimethylamino)acrylate
C24H25ClN4O4
Acta Crystallographica Section E (2005) 61, 11 o3879-o3880
a=16.088(3)Å b=8.3060(17)Å c=17.358(4)Å
α=90.00° β=95.79(3)° γ=90.00°
1-[(2,6-Dimethylphenyl)aminocarbonylmethyl]4-{[3-(3-methoxyphenyl)- 1,2,4-oxadiazol-5-yl]methyl}piperazine
C24H29N5O3
Acta Crystallographica Section E (2005) 61, 11 o3750-o3751
a=17.120(3)Å b=10.271(2)Å c=13.042(3)Å
α=90.00° β=91.10(3)° γ=90.00°
Methyl 2-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenylacetate
C18H15BrN2O4
Acta Crystallographica Section E (2006) 62, 3 o1131-o1132
a=20.011(4)Å b=9.643(2)Å c=18.089(4)Å
α=90.00° β=98.33(3)° γ=90.00°
Methyl 2-(2-{1-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]-2- (dimethylamino)vinyloxy}phenyl)-3-(dimethylamino)acrylate
C24H25BrN4O4
Acta Crystallographica Section E (2006) 62, 8 o3467-o3468
a=15.479(3)Å b=8.5690(17)Å c=17.919(4)Å
α=90.00° β=98.37(3)° γ=90.00°
Methyl 2-{[3-(4-methylsulfanyl)phenyl-1,2,4-oxadiazol- 5-yl]methoxy}phenylacetate
C19H18N2O4S
Acta Crystallographica Section E (2004) 60, 11 o2122-o2124
a=8.3580(17)Å b=10.522(2)Å c=10.581(2)Å
α=90.13(3)° β=102.08(3)° γ=99.73(3)°
Methyl 2-(2-{1-[3-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-2- (dimethylamino)vinyloxy}phenyl)-3-(dimethylamino)acrylate
C26H30N4O6
Acta Crystallographica Section E (2004) 60, 11 o2070-o2072
a=8.6500(17)Å b=10.700(2)Å c=14.817(3)Å
α=107.66(3)° β=97.50(3)° γ=95.15(3)°
Methyl 2-{[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]methoxy}phenylacetate
C18H15N3O6
Acta Crystallographica Section E (2004) 60, 11 o2073-o2075
a=10.436(2)Å b=5.1800(10)Å c=31.560(6)Å
α=90.00° β=92.94(3)° γ=90.00°
2-(3-Phenyl-1,2,4-oxadiazol-5-yl)-4H-1-benzopyran-3-ol
C17H12N2O3
Acta Crystallographica Section E (2004) 60, 11 o1917-o1918
a=5.6750(10)Å b=9.346(2)Å c=25.440(5)Å
α=90.00° β=92.06(3)° γ=90.00°
1-{[3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl]methyl}-4-[(2,6- dimethylphenyl)aminocarbonylmethyl]piperazine
C23H26BrN5O2
Acta Crystallographica Section E (2006) 62, 8 o3465-o3466
a=7.2000(14)Å b=9.5300(19)Å c=33.089(7)Å
α=90.00° β=94.71(3)° γ=90.00°
2-(2,2-dichloroacetylamino)-3-methyl butyric acid hydrate (1/0.41)
C7H11Cl2NO3,0.41H2O
Acta Crystallographica Section E (2003) 59, 7 o1043-o1044
a=9.298(2)Å b=9.0110(10)Å c=13.990(2)Å
α=90.00° β=108.070(10)° γ=90.00°
Methyl 3-(dimethylamino)-2-[2-(1-{3-[4-(methylsulfanyl)phenyl]-1,2,4-oxadiazol-5-yl}- 2-(dimethylamino)vinyloxy)phenyl]acrylate
C25H28N4O4S
Acta Crystallographica Section E (2005) 61, 1 o58-o59
a=8.2940(17)Å b=12.654(3)Å c=23.601(5)Å
α=90.00° β=97.02(3)° γ=90.00°
Methyl 3-dimethylamino-2-(2-{2-dimethylamino-1-[3-(3-pyridyl)-1,2,4-oxadiazol- 5-yl]vinyloxy}phenyl)acrylate
C23H25N5O4
Acta Crystallographica Section E (2005) 61, 4 o1010-o1012
a=8.6250(17)Å b=9.6390(19)Å c=26.273(5)Å
α=90.00° β=91.28(3)° γ=90.00°
5-Chloromethyl-3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazole
C10H9ClN2O3S
Acta Crystallographica Section E (2005) 61, 4 o953-o954
a=5.6170(11)Å b=12.247(2)Å c=16.993(3)Å
α=90.00° β=93.06(3)° γ=90.00°
1-Acetyl-3,3-bis[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-indolin-2(3H)-one
C30H25N5O4
Acta Crystallographica Section E (2006) 62, 3 o917-o918
a=11.680(2)Å b=12.234(2)Å c=18.396(4)Å
α=90.00° β=93.85(3)° γ=90.00°
[3-(2-Methylphenyl)-1,2,4-oxadiazol-5-yl]methanol
C10H10N2O2
Acta Crystallographica Section E (2006) 62, 4 o1302-o1303
a=7.529(2)Å b=14.307(3)Å c=8.799(3)Å
α=90.00° β=106.39(3)° γ=90.00°
5-Bromo-2-iodopyrimidine
C4H2BrIN2
Acta Crystallographica Section E (2006) 62, 10 o4238-o4239
a=6.1410(12)Å b=6.7890(14)Å c=16.071(3)Å
α=90.00° β=90.00° γ=90.00°
3-Methoxybenzamide oxime
C8H10N2O2
Acta Crystallographica Section E (2006) 62, 10 o4243-o4244
a=6.8630(14)Å b=18.910(4)Å c=12.893(3)Å
α=90.00° β=101.77(3)° γ=90.00°
[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]methanol
C9H7ClN2O2
Acta Crystallographica Section E (2006) 62, 10 o4226-o4227
a=27.789(2)Å b=4.0141(5)Å c=21.4570(15)Å
α=90.00° β=127.56(3)° γ=90.00°
N-(2,6-Dimethylphenyl)-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]acetamide
C24H21N3O3
Acta Crystallographica Section E (2006) 62, 11 o4950-o4951
a=12.685(3)Å b=20.073(4)Å c=8.3090(17)Å
α=90.00° β=102.87(3)° γ=90.00°
2-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenol
C14H9ClN2O2
Acta Crystallographica Section E (2006) 62, 12 o5592-o5593
a=6.3900(13)Å b=5.0380(10)Å c=19.255(4)Å
α=90.00° β=97.98(3)° γ=90.00°
N-(2,6-Dimethylphenyl)-2-{2-[3-(3-methoxyphenyl)-1,2,4-oxadiazol- 5-yl]phenoxy}acetamide
C25H23N3O4
Acta Crystallographica Section E (2006) 62, 12 o5574-o5575
a=8.0360(16)Å b=11.692(2)Å c=12.780(3)Å
α=66.93(3)° β=85.56(3)° γ=81.18(3)°
2-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenol
C15H12N2O2
Acta Crystallographica Section E (2006) 62, 12 o5840-o5841
a=6.5110(13)Å b=5.1720(10)Å c=18.763(4)Å
α=90.00° β=99.14(3)° γ=90.00°
2-Chlorobenzamide oxime monohydrate
C7H7ClN2O,H2O
Acta Crystallographica Section E (2007) 63, 2 o1019-o1020
a=4.5550(9)Å b=6.8790(14)Å c=28.715(6)Å
α=91.37(3)° β=90.58(3)° γ=101.21(3)°
6,6'-Bis(2H-1,2,3-benzotriazol-2-yl)-4,4'-bis(2,4,4-trimethylpentan-2-yl)- 2,2'-methylenebiphenol
C41H50N6O2
Acta Crystallographica Section E (2007) 63, 2 o819-o820
a=18.302(4)Å b=8.0960(16)Å c=24.553(5)Å
α=90.00° β=90.00° γ=90.00°
3,5-Dimethoxybenzamide oxime
C9H12N2O3
Acta Crystallographica Section E (2007) 63, 7 o3279-o3279
a=6.4390(13)Å b=8.0840(16)Å c=10.188(2)Å
α=71.29(3)° β=81.60(3)° γ=74.21(3)°
N-(2,6-Dimethylphenyl)- 2-(2-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}phenoxy)acetamide
C25H23N3O5S
Acta Crystallographica Section E (2007) 63, 9 o3668-o3668
a=28.848(6)Å b=13.648(3)Å c=13.562(3)Å
α=90.00° β=117.58(3)° γ=90.00°
N'-Hydroxynicotinamidine
C6H7N3O
Acta Crystallographica Section E (2007) 63, 10 o4151-o4151
a=5.5220(11)Å b=12.365(3)Å c=9.797(2)Å
α=90.00° β=94.38(3)° γ=90.00°
2-tert-Butyl 4-ethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate
C14H21NO4
Acta Crystallographica Section E (2007) 63, 10 o4186-o4186
a=18.570(4)Å b=7.1420(14)Å c=12.431(3)Å
α=90.00° β=116.46(3)° γ=90.00°
2-Chloro-3-(2,2,2-trifluoroethoxy)pyridine
C7H5ClF3NO
Acta Crystallographica Section E (2007) 63, 11 o4355-o4355
a=12.907(3)Å b=7.469(2)Å c=18.520(4)Å
α=90.00° β=90.00° γ=90.00°
2-{2-[3-(3,5-Dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]phenoxy}- N-(2,6-dimethylphenyl)acetamide
C26H25N3O5
Acta Crystallographica Section E (2007) 63, 11 o4314-o4314
a=7.3200(15)Å b=12.630(3)Å c=13.106(3)Å
α=95.37(3)° β=101.06(3)° γ=103.48(3)°
5-Chloromethyl-3-(3,5-dimethoxyphenyl)-1,2,4-oxadiazole
C11H11ClN2O3
Acta Crystallographica Section E (2007) 63, 11 o4234-o4234
a=7.861(2)Å b=8.502(2)Å c=9.537(2)Å
α=80.72(3)° β=73.90(3)° γ=70.09(3)°
2-{[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]methylsulfanyl}-5-methyl- 1,3,4-thiadiazole
C12H9ClN4OS2
Acta Crystallographica Section E (2007) 63, 11 o4411-o4411
a=5.8570(10)Å b=27.104(5)Å c=9.026(2)Å
α=90.00° β=102.85(3)° γ=90.00°
2-Methyl-5-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-ylmethylenesulfanyl]-1,3,4- thiadiazole
C12H9N5O3S2
Acta Crystallographica Section E (2007) 63, 11 o4236-o4236
a=35.939(7)Å b=5.6540(11)Å c=13.714(3)Å
α=90.00° β=92.55(3)° γ=90.00°
2-Methyl-5-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-ylmethylsulfanyl}- 1,3,4-thiadiazole
C13H12N4O3S3
Acta Crystallographica Section E (2007) 63, 11 o4356-o4356
a=12.365(3)Å b=15.956(3)Å c=8.2400(16)Å
α=90.00° β=108.26(3)° γ=90.00°
2-Methyl-5-{[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methylsulfanyl}- 1,3,4-thiadiazole
C13H12N4OS2
Acta Crystallographica Section E (2007) 63, 12 o4934-o4934
a=16.751(3)Å b=10.686(2)Å c=8.0940(16)Å
α=90.00° β=97.12(3)° γ=90.00°
N-acryloylglycylglycine monohydrate
C7H10N2O4,H2O
Acta Crystallographica Section E (2007) 63, 12 o4580-o4580
a=13.332(3)Å b=5.1490(10)Å c=14.458(3)Å
α=90.00° β=103.09(3)° γ=90.00°
3-(3-Methoxyphenyl)-5-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]- 1,2,4-oxadiazole
C13H12N4O2S2
Acta Crystallographica Section E (2007) 63, 12 o4776-o4776
a=6.1390(10)Å b=9.890(2)Å c=12.658(3)Å
α=72.45(3)° β=85.91(3)° γ=77.12(3)°
3,4-Dibutoxy-<i>N</i>^2^,<i>N</i>^2'^-bis(propan-2-ylidene)thiophene-2,5- dicarbohydrazide
C20H32N4O4S
Acta Crystallographica Section E (2007) 63, 12 o4762-o4762
a=20.891(4)Å b=10.526(2)Å c=13.581(3)Å
α=90.00° β=128.24(3)° γ=90.00°
Ethyl 5-formyl-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylate
C10H13NO3
Acta Crystallographica Section E (2008) 64, 6 o1125
a=3.9830(8)Å b=15.572(3)Å c=16.213(3)Å
α=90.00° β=96.96(3)° γ=90.00°
2-Chloro-<i>N</i>-(4-fluorophenyl)acetamide
C8H7ClFNO
Acta Crystallographica Section E (2008) 64, 7 o1194
a=4.7410(9)Å b=20.062(4)Å c=8.9860(18)Å
α=90.00° β=99.60(3)° γ=90.00°
2-Methyl-5-[(3-phenyl-1,2,4-oxadiazol-5-yl)methylsulfanyl]-1,3,4-thiadiazole
C12H10N4OS2
Acta Crystallographica Section E (2007) 63, 10 o4180-o4180
a=9.926(2)Å b=5.9340(12)Å c=23.049(5)Å
α=90.00° β=100.39(3)° γ=90.00°
2-Methylbenzamidoxime
C8H10N2O
Acta Crystallographica Section E (2007) 63, 2 o487-o488
a=9.751(2)Å b=7.0880(14)Å c=11.982(2)Å
α=90.00° β=98.60(3)° γ=90.00°
4-Nitrobenzamidoxime
C7H7N3O3
Acta Crystallographica Section E (2007) 63, 2 o489-o490
a=11.320(2)Å b=7.7760(16)Å c=18.802(4)Å
α=90.00° β=90.00° γ=90.00°
2-[3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl]phenol
C14H9BrN2O2
Acta Crystallographica Section E (2007) 63, 12 o4697-o4697
a=6.3950(13)Å b=5.0790(10)Å c=19.625(4)Å
α=90.00° β=98.65(3)° γ=90.00°
2-(2-{3-[4-(Dimethylamino)phenyl]-1,2,4-oxadiazol-5-yl}phenoxy)-\ N-(2,6-dimethylphenyl)acetamide
C26H26N4O3
Acta Crystallographica Section E (2007) 63, 12 o4745-o4745
a=8.9900(18)Å b=9.0330(18)Å c=15.445(3)Å
α=83.01(3)° β=79.76(3)° γ=66.54(3)°
2-Methyl-5-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-ylmethylsulfanyl]- 1,3,4-thiadiazole
C13H12N4OS2
Acta Crystallographica Section E (2007) 63, 12 o4586-o4586
a=10.309(2)Å b=12.992(3)Å c=10.600(2)Å
α=90.00° β=100.63(3)° γ=90.00°
4-(3-(Chloromethyl)-1,2,4-oxadiazol-5-yl)pyridine
C8H6ClN3O
Acta Crystallographica Section E (2007) 63, 12 o4654-o4654
a=10.512(2)Å b=11.486(2)Å c=7.2080(14)Å
α=90.00° β=94.11(3)° γ=90.00°
5-(Chloromethyl)-3-(2-chlorophenyl)-1,2,4-oxadiazole
C9H6Cl2N2O
Acta Crystallographica Section E (2007) 63, 12 o4746-o4746
a=10.396(2)Å b=10.302(2)Å c=9.2070(18)Å
α=90.00° β=98.30(3)° γ=90.00°
4-Chlorobenzamidoxime
C7H7ClN2O
Acta Crystallographica Section E (2007) 63, 12 o4698-o4698
a=7.9930(16)Å b=12.806(3)Å c=7.6740(15)Å
α=90.00° β=90.96(3)° γ=90.00°
2-[3,4-Dibutoxy-5-(5-phenyl-1,3,4-oxadiazol-2-yl)-2-thienyl]- 5-phenyl-1,3,4-oxadiazole
C28H28N4O4S
Acta Crystallographica Section E (2008) 64, 8 o1419
a=7.6770(15)Å b=16.871(3)Å c=20.398(4)Å
α=90.00° β=93.77(3)° γ=90.00°
N-acryloylphenylalanie
C12H13NO3
Acta Crystallographica Section E (2008) 64, 8 o1483
a=6.0050(12)Å b=7.5820(15)Å c=12.512(3)Å
α=90.00° β=98.58(3)° γ=90.00°
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
C14H18N2O2
Acta Crystallographica Section E (2006) 62, 9 o3838-o3839
a=6.3390(13)Å b=9.3130(19)Å c=22.712(5)Å
α=90.00° β=90.00° γ=90.00°
Methyl {2-[3-(2,4-dichlorophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenyl}acetate
C18H14Cl2N2O4
Acta Crystallographica Section E (2006) 62, 10 o4405-o4406
a=7.4910(15)Å b=15.613(3)Å c=15.100(3)Å
α=90.00° β=90.59(3)° γ=90.00°
1-Acetyl-3,3-bis[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-ylmethyl]indolin-2-one
C30H25N5O6
Acta Crystallographica Section E (2006) 62, 10 o4640-o4641
a=8.6300(17)Å b=11.866(2)Å c=14.616(3)Å
α=108.95(3)° β=99.02(3)° γ=101.17(3)°
2-{2-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenoxy}- N-(2,6-dimethylphenyl)acetamide
C24H20ClN3O3
Acta Crystallographica Section E (2006) 62, 10 o4744-o4745
a=12.498(3)Å b=8.2410(16)Å c=20.996(4)Å
α=90.00° β=93.21(3)° γ=90.00°
N-(2,6-Dimethylphenyl)-2-(2-{3-[4-(methylsulfanyl)phenyl]-1,2,4-oxadiazol- 5-yl}phenoxy)acetamide
C25H23N3O3S
Acta Crystallographica Section E (2007) 63, 4 o1683-o1684
a=8.6160(17)Å b=9.2900(19)Å c=15.225(3)Å
α=84.34(3)° β=81.45(3)° γ=66.66(3)°
4-(Methylsulfanyl)benzamide oxime
C8H10N2OS
Acta Crystallographica Section E (2007) 63, 4 o1834-o1835
a=10.221(2)Å b=11.882(2)Å c=17.120(3)Å
α=74.12(3)° β=72.91(3)° γ=64.94(3)°
N-(2,6-Dimethylphenyl)-2-{2-[3-(4-fluorophenyl)-1,2,4-oxadiazol- 5-yl]phenoxy}acetamide
C24H20FN3O3
Acta Crystallographica Section E (2007) 63, 5 o2062-o2063
a=12.143(2)Å b=8.1850(16)Å c=20.942(4)Å
α=90.00° β=90.52(3)° γ=90.00°
4-Bromobenzamide oxime
C7H7BrN2O
Acta Crystallographica Section E (2007) 63, 5 o2236-o2237
a=8.1347(16)Å b=12.964(3)Å c=7.6517(15)Å
α=90.00° β=90.41(3)° γ=90.00°
5-Chloromethyl-3-(4-methylphenyl)-1,2,4-oxadiazole
C10H9ClN2O
Acta Crystallographica Section E (2007) 63, 12 o4619-o4619
a=25.462(5)Å b=6.4040(13)Å c=14.589(3)Å
α=90.00° β=122.83(3)° γ=90.00°
4-Methoxybenzamide oxime
C8H10N2O2
Acta Crystallographica Section E (2007) 63, 12 o4763-o4763
a=14.924(3)Å b=5.0820(10)Å c=10.784(2)Å
α=90.00° β=98.32(3)° γ=90.00°
6,10,16,19-Tetraoxatrispiro[4.2.2.4.2.2]nonadecane
C15H24O4
Acta Crystallographica Section E (2008) 64, 2 o498-o498
a=25.605(5)Å b=5.5820(11)Å c=10.337(2)Å
α=90° β=90.22(3)° γ=90°
2-(4-<i>tert</i>-Butylphenyl)-5-{3,4-dibutoxy-5-[5-(4-<i>tert</i>-butylphenyl)- 1,3,4-oxadiazol-2-yl]-2-thienyl}-1,3,4-oxadiazole
C36H44N4O4S
Acta Crystallographica Section E (2008) 64, 11 o2154
a=19.421(4)Å b=17.387(4)Å c=10.424(2)Å
α=90.00° β=94.24(3)° γ=90.00°
5,5'-Diethyl-2,2'-(triazene-1,3-diyl)di-1,3,4-thiadiazole
C8H11N7S2
Acta Crystallographica Section E (2008) 64, 11 o2166
a=12.188(2)Å b=9.1460(18)Å c=12.790(3)Å
α=90.00° β=110.99(3)° γ=90.00°
5-chloromethyl-3-(2,4-dichlorophenyl)-1,2,4-oxadiazole
C9H5Cl3N2O
Acta Crystallographica Section E (2006) 62, 10 o4715-o4716
a=7.9010(16)Å b=14.987(3)Å c=9.7400(19)Å
α=90.00° β=113.20(3)° γ=90.00°
2-{2-[3-(2-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenoxy}- N-(2,6-dimethylphenyl)acetamide
C24H20ClN3O3
Acta Crystallographica Section E (2006) 62, 11 o5280-o5281
a=8.9110(18)Å b=10.612(2)Å c=12.491(3)Å
α=94.55(3)° β=92.09(3)° γ=114.63(3)°